[144] AGIOS PHARMACEUTICALS, INC. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Agios Pharmaceuticals (AGIO) reporting proposed sale of common shares by an insider. The notice identifies David T. Scadden as the person for whose account the securities will be sold. The filing shows 200 shares intended for sale through Morgan Stanley Smith Barney LLC on 09/30/2025 with an aggregate market value of $8,000. The shares were acquired by a stock option exercise on 09/30/2025 and paid for in cash. The filing also discloses two prior sales by the reporting person within the past three months: 200 shares on 08/27/2025 for $8,000 and 1,400 shares on 07/10/2025 for $56,000. The notice includes the required representation that the seller does not possess undisclosed material adverse information.

Positive

• Disclosure compliance: The filer has submitted a Form 144 with broker details and transaction dates, meeting Rule 144 reporting requirements.
• Transaction transparency: The filing specifies acquisition method (stock option exercise), payment in cash, and broker information.

Negative

• Insider selling activity: The reporting person sold 1,600 shares in the past three months for gross proceeds of $64,000, which may attract investor attention.
• No 10b5-1 plan date provided: The form does not indicate a trading-plan adoption date, so sales are not documented as pre-planned in this filing.

Insights

Securities Analyst

TL;DR: An insider reported small, routine sales totaling 1,600 shares over three months; the new planned sale is 200 shares valued at $8,000.

The filing documents routine Rule 144 reporting for insider sales rather than corporate events. The prospective sale of 200 shares (aggregate market value $8,000) was acquired by option exercise and is to be sold through Morgan Stanley on 09/30/2025. Recent historical sales by the same person total 1,600 shares and $64,000 in gross proceeds across July and August 2025, which provides transparency about the insider's recent disposition activity. Given the absolute size of the transactions relative to 58,101,518 shares outstanding, these sales appear small in scale and consistent with individual liquidity events rather than company-level developments.

Corporate Governance Expert

TL;DR: Filing meets Rule 144 disclosure requirements; no plan adoption date or 10b5-1 plan is indicated.

The notice includes the statutory certification regarding absence of undisclosed material adverse information and lists broker details and transaction mechanics (option exercise paid in cash). The form does not indicate reliance on a written trading plan or provide a plan adoption date, so the sale appears reported as a discretionary or post-exercise sale under Rule 144. From a governance perspective, the document demonstrates compliance with reporting rules but contains no information on an ongoing trading plan that might demonstrate pre-commitment to sales.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	200	8000.00	58101518	09/30/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/30/2025	Stock Option Exercise	Issuer			200	09/30/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DAVID T. SCADDEN 88 Sidney St. Cambridge MA 02139	Common	08/27/2025	200	8000.00
DAVID SCADDEN 88 Sidney St. Cambridge MA 02139	Common	07/10/2025	1400	56000.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Who is the filer in the AGIO Form 144 filing?

The filing names David T. Scadden as the person for whose account the securities are to be sold.

How many AGIO shares are proposed to be sold on 09/30/2025?

The filer proposes to sell 200 common shares on 09/30/2025 with an aggregate market value of $8,000.

How were the shares that are to be sold acquired?

The 200 shares were acquired via a stock option exercise on 09/30/2025 and payment was made in cash.

What recent AGIO sales by the filer are disclosed in the Form 144?

The filing discloses two prior sales: 200 shares on 08/27/2025 for $8,000 and 1,400 shares on 07/10/2025 for $56,000.

Through which broker will the AGIO shares be sold?

The filing lists Morgan Stanley Smith Barney LLC as the broker handling the proposed sale.